We are live on
!
Find out more
Vanguard Capital Management Portfolio holdings
AUM
$4.68T
This Fund
S&P 500
This Quarter
Est. Return
-1.1%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.04T
AUM Growth
–
Cap. Flow
+$4.22T
Cap. Flow
% of AUM
104.32%
Top 10 Holdings %
Top 10 Hldgs %
32.57%
Holding
4,062
New
4,062
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$282B |
| 2 |
Apple
AAPL
|
+$248B |
| 3 |
Microsoft
MSFT
|
+$202B |
| 4 |
Amazon
AMZN
|
+$139B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$119B |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.5% |
| 2 | Financials | 12.85% |
| 3 | Healthcare | 9.93% |
| 4 | Consumer Discretionary | 9.89% |
| 5 | Communication Services | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2501
Nu Skin
NUS
$228M
| $15M | ﹤0.01% |
+2,063,350
| New | +$18.7M |
|
2502
Aura Biosciences
AURA
$846M
| $15M | ﹤0.01% |
+2,243,828
| New | +$12.9M |
|
|
AKTS
2503
Aktis Oncology
AKTS
$1.37B
| $14.9M | ﹤0.01% |
+833,913
| New | +$16.2M |
|
2504
Enanta Pharmaceuticals
ENTA
$374M
| $14.9M | ﹤0.01% |
+1,178,049
| New | +$15.8M |
|
2505
Lexicon Pharmaceuticals
LXRX
$1.08B
| $14.8M | ﹤0.01% |
+9,519,167
| New | +$13.8M |
|
2506
Cerus
CERS
$556M
| $14.8M | ﹤0.01% |
+8,131,778
| New | +$17.7M |
|
2507
Neuropace
NPCE
$490M
| $14.8M | ﹤0.01% |
+1,123,711
| New | +$16.9M |
|
2508
Capital Bancorp
CBNK
$613M
| $14.8M | ﹤0.01% |
+496,749
| New | +$14.9M |
|
2509
Orange County Bancorp
OBT
$519M
| $14.8M | ﹤0.01% |
+461,702
| New | +$14.7M |
|
2510
Rapid7
RPD
$849M
| $14.7M | ﹤0.01% |
+2,676,030
| New | +$24.6M |
|
2511
Richtech Robotics
RR
$360M
| $14.7M | ﹤0.01% |
+7,054,719
| New | +$21.7M |
|
|
CBIO
2512
Crescent Biopharma
CBIO
$649M
| $14.7M | ﹤0.01% |
+801,395
| New | +$9.2M |
|
2513
Lightbridge
LTBR
$299M
| $14.6M | ﹤0.01% |
+1,374,016
| New | +$19.1M |
|
2514
Shattuck Labs
STTK
$742M
| $14.6M | ﹤0.01% |
+2,277,176
| New | +$10.8M |
|
|
TECX
2515
Tectonic Therapeutic
TECX
$716M
| $14.6M | ﹤0.01% |
+473,532
| New | +$11.7M |
|
|
MPLT
2516
MapLight Therapeutics
MPLT
$548M
| $14.6M | ﹤0.01% |
+719,820
| New | +$12.9M |
|
|
MAGN
2517
Magnera Corp
MAGN
$427M
| $14.6M | ﹤0.01% |
+1,533,277
| New | +$19.6M |
|
2518
Ponce Financial Group
PDLB
$502M
| $14.5M | ﹤0.01% |
+870,366
| New | +$14.3M |
|
2519
Helen of Troy
HELE
$656M
| $14.5M | ﹤0.01% |
+1,006,864
| New | +$17.6M |
|
|
ILPT
2520
Industrial Logistics Properties Trust
ILPT
$563M
| $14.5M | ﹤0.01% |
+2,555,760
| New | +$14.9M |
|
2521
Titan International
TWI
$414M
| $14.5M | ﹤0.01% |
+2,094,937
| New | +$18.8M |
|
2522
X4 Pharmaceuticals
XFOR
$417M
| $14.4M | ﹤0.01% |
+3,497,612
| New | +$13.1M |
|
|
ABX
2523
Abacus Global Management
ABX
$881M
| $14.4M | ﹤0.01% |
+1,831,610
| New | +$15.9M |
|
2524
Climb Global Solutions
CLMB
$520M
| $14.4M | ﹤0.01% |
+727,280
| New | +$18.8M |
|
2525
iHeartMedia
IHRT
$466M
| $14.4M | ﹤0.01% |
+4,935,932
| New | +$16.3M |
|
Similar funds
Vanguard Capital Management's Q1 2026 Portfolio in Review
Q1 2026 is the first quarter with a 13F filing on record for Vanguard Capital Management, which disclosed 4,062 positions worth $4.04T. Its ten largest holdings account for 33% of the portfolio.
Its largest position is NVIDIA: 1,538,550,382 shares worth $268B.
By sector, the portfolio is most concentrated in Technology at 31% of assets, followed by Financials and Healthcare.
- Vanguard Capital Management's largest Q1 2026 buy was NVIDIA: 1,538,550,382 shares worth $268B.
- Vanguard Capital Management's ten largest holdings make up 33% of its $4.04T portfolio in Q1 2026.
- Vanguard Capital Management disclosed 4,062 positions in Q1 2026, its first 13F filing on record.
Based on Vanguard Capital Management's 13F filing for Q1 2026, filed 8 May 2026.